Dong-Hoon Jin(CEO, Wellmarker Bio) has signed research agreement with Hyun-sang Mook(CEO, Korea Drug Development Fund) on March 20, 2018. Through this agreement Wellmarker Bio will promote new drug development for NSCLC cancer patients with its new mechanism of action.
Link: http://news.mk.co.kr/v2/economy/view.php?year=2018&no=182071
Link: http://news.mk.co.kr/v2/economy/view.php?year=2018&no=182071